These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 22465283)
1. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Malekzadeh A; de Groot V; Beckerman H; van Oosten BW; Blankenstein MA; Teunissen C Methods; 2012 Apr; 56(4):508-13. PubMed ID: 22465283 [TBL] [Abstract][Full Text] [Related]
2. Development of a bead-based multiplex assay for the simultaneous detection of porcine inflammation markers using xMAP technology. Bongoni AK; Lanz J; Rieben R; Banz Y Cytometry A; 2013 Jul; 83(7):636-47. PubMed ID: 23576245 [TBL] [Abstract][Full Text] [Related]
3. Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease. Lasseter HC; Provost AC; Chaby LE; Daskalakis NP; Haas M; Jeromin A Cytokine X; 2020 Jun; 2(2):100027. PubMed ID: 33604555 [TBL] [Abstract][Full Text] [Related]
4. Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. Malekzadeh A; Twaalfhoven H; Wijnstok NJ; Killestein J; Blankenstein MA; Teunissen CE Cytokine; 2017 Mar; 91():145-152. PubMed ID: 28082233 [TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of cytokines in Alzheimer's disease. Swardfager W; Lanctôt K; Rothenburg L; Wong A; Cappell J; Herrmann N Biol Psychiatry; 2010 Nov; 68(10):930-41. PubMed ID: 20692646 [TBL] [Abstract][Full Text] [Related]
6. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Vawter MP; Dillon-Carter O; Tourtellotte WW; Carvey P; Freed WJ Exp Neurol; 1996 Dec; 142(2):313-22. PubMed ID: 8934562 [TBL] [Abstract][Full Text] [Related]
9. How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays. Belzeaux R; Lefebvre MN; Lazzari A; Le Carpentier T; Consoloni JL; Zendjidjian X; Abbar M; Courtet P; Naudin J; Boucraut J; Gressens P; Glaichenhaus N; Ibrahim EC Psychoneuroendocrinology; 2017 Jan; 75():72-82. PubMed ID: 27810706 [TBL] [Abstract][Full Text] [Related]
10. Cytokine mapping in cerebrospinal fluid and blood in multiple sclerosis patients without oligoclonal bands. Vrethem M; Kvarnström M; Stenstam J; Cassel P; Gustafsson M; Landtblom AM; Ernerudh J Mult Scler; 2012 May; 18(5):669-73. PubMed ID: 21965416 [TBL] [Abstract][Full Text] [Related]
11. Systems approach to neurodegenerative disease biomarker discovery. Lausted C; Lee I; Zhou Y; Qin S; Sung J; Price ND; Hood L; Wang K Annu Rev Pharmacol Toxicol; 2014; 54():457-81. PubMed ID: 24160693 [TBL] [Abstract][Full Text] [Related]
12. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Maurer MH Mass Spectrom Rev; 2010; 29(1):17-28. PubMed ID: 19116946 [TBL] [Abstract][Full Text] [Related]
13. Identification of glycoproteins in human cerebrospinal fluid. Hwang HJ; Quinn T; Zhang J Methods Mol Biol; 2009; 566():263-76. PubMed ID: 20058177 [TBL] [Abstract][Full Text] [Related]
14. [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders]. Gabelle A; Roche S; Lehmann S Rev Neurol (Paris); 2009 Mar; 165(3):213-22. PubMed ID: 18808768 [TBL] [Abstract][Full Text] [Related]
15. Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. Herbert MK; Kuiperij HB; Verbeek MM J Immunol Methods; 2012 Jul; 381(1-2):1-8. PubMed ID: 22542401 [TBL] [Abstract][Full Text] [Related]
16. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Sheta EA; Appel SH; Goldknopf IL Expert Rev Proteomics; 2006 Feb; 3(1):45-62. PubMed ID: 16445350 [TBL] [Abstract][Full Text] [Related]
17. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206 [TBL] [Abstract][Full Text] [Related]
19. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. Kruse N; Schulz-Schaeffer WJ; Schlossmacher MG; Mollenhauer B Methods; 2012 Apr; 56(4):514-8. PubMed ID: 22465793 [TBL] [Abstract][Full Text] [Related]
20. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Otto M; Lewczuk P; Wiltfang J Methods; 2008 Apr; 44(4):289-98. PubMed ID: 18374272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]